Stocks · News reference
Ascendiant Capital analyst Edward Woo maintains Cerenome (NASDAQ:CNSY) with a Buy and lowers the price target from $57 to $43.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-09-10 AccNo: 0001193125-26-387267 Size: 2 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Capital will support continued CNSide® commercial scale-up and developmentInitial tranche of funding provided at closing with future tranches linked to milestonesForecasted cash runway now into 2028HOUSTON, Sept. 10,
Under the agreement, the Company received initial funding at closing, with future tranches available upon achieving certain milestones. The financing is intended to support the scale-up of the Company’s proprietary